Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M C Favrot

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
Bulletin Du Cancer|January 1, 1988
[Intensive chemotherapy and bone marrow grafting during the consolidation phase of stage IV neuroblastoma]T Philip, J M Zucker, J L Bernard, et al.
Bone Marrow Transplantation|September 1, 1989
Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantationM C Favrot, D Floret, S Negrier, et al.
Archives Francaises De Pediatrie|November 1, 1987
[Detection of residual cells contaminating the bone marrow in neuroblastoma. Apropos of 80 bone marrow evaluations]D Frappaz, O Maritaz, M C Favrot, et al.
British Journal of Cancer|January 1, 1997
Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinomaC Bain, Y Merrouche, I Puisieux, et al.
Medical and Pediatric Oncology|February 1, 1997
Screening for neuroblastoma in France: methodological aspects and preliminary observationsF Chauvin, P Mathieu, D Frappaz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 1, 1996
Comparison of the diagnostic and prognostic value of biological markers in neuroblastoma. Proposal for a common methodology of analysis. SENSE groupM C Favrot, P Ambros, F Schilling, et al.
International Journal of Cancer|March 27, 2001
Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplificationD Plantaz, J Vandesompele, N Van Roy, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Bulletin Du Cancer|January 1, 1988
[Intensive chemotherapy and bone marrow grafting during the consolidation phase of stage IV neuroblastoma]T Philip, J M Zucker, J L Bernard, et al.
Bone Marrow Transplantation|September 1, 1989
Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantationM C Favrot, D Floret, S Negrier, et al.
Archives Francaises De Pediatrie|November 1, 1987
[Detection of residual cells contaminating the bone marrow in neuroblastoma. Apropos of 80 bone marrow evaluations]D Frappaz, O Maritaz, M C Favrot, et al.
British Journal of Cancer|January 1, 1997
Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinomaC Bain, Y Merrouche, I Puisieux, et al.
Medical and Pediatric Oncology|February 1, 1997
Screening for neuroblastoma in France: methodological aspects and preliminary observationsF Chauvin, P Mathieu, D Frappaz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 1, 1996
Comparison of the diagnostic and prognostic value of biological markers in neuroblastoma. Proposal for a common methodology of analysis. SENSE groupM C Favrot, P Ambros, F Schilling, et al.
International Journal of Cancer|March 27, 2001
Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplificationD Plantaz, J Vandesompele, N Van Roy, et al.
Pageof 8